Kulikowska de Nałęcz, A.; Ciszak, L.; Usnarska-Zubkiewicz, L.; Pawlak, E.; Frydecka, I.; Szmyrka, M.; Kosmaczewska, A.
Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. Int. J. Mol. Sci. 2023, 24, 5730.
https://doi.org/10.3390/ijms24065730
AMA Style
Kulikowska de Nałęcz A, Ciszak L, Usnarska-Zubkiewicz L, Pawlak E, Frydecka I, Szmyrka M, Kosmaczewska A.
Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. International Journal of Molecular Sciences. 2023; 24(6):5730.
https://doi.org/10.3390/ijms24065730
Chicago/Turabian Style
Kulikowska de Nałęcz, Anna, Lidia Ciszak, Lidia Usnarska-Zubkiewicz, Edyta Pawlak, Irena Frydecka, Magdalena Szmyrka, and Agata Kosmaczewska.
2023. "Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors" International Journal of Molecular Sciences 24, no. 6: 5730.
https://doi.org/10.3390/ijms24065730
APA Style
Kulikowska de Nałęcz, A., Ciszak, L., Usnarska-Zubkiewicz, L., Pawlak, E., Frydecka, I., Szmyrka, M., & Kosmaczewska, A.
(2023). Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors. International Journal of Molecular Sciences, 24(6), 5730.
https://doi.org/10.3390/ijms24065730
